TNYA at a glance
Tenaya Therapeutics Inc (TNYA, SEC CIK 1858848) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Tenaya Therapeutics Inc (TNYA) shares worth $21.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ali Faraz on August 17, 2026 of 5,837 shares at $0.71 per share.
- In the last 90 days, TNYA insiders reported 0 open-market purchases ($0) and 8 open-market sales ($21K) on Form 4, a net sale of $21K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$21K
- 13F holders
- 21 funds
- $21.6M · −1 vs prior quarter
- Latest 10-Q
- Aug 5, 2026
- Quarterly report
SignalX for TNYA
Don't miss the next TNYA filing
- Alerts as it files. A push when TNYA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TNYA, by share count.
- Ask anything. An AI agent that reads every TNYA filing and answers with sources.
TNYA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ali Faraz | A | Sep 10, 2026 | 732,500 | - |
| Ali Faraz | A | Sep 10, 2026 | 122,000 | - |
| Tingley Whittemore | A | Sep 10, 2026 | 49,000 | - |
| Tingley Whittemore | A | Sep 10, 2026 | 293,000 | - |
| Ali Faraz | Sell | Aug 17, 2026 | 5,837 | $0.71 |
| Tingley Whittemore | Sell | Aug 17, 2026 | 1,871 | $0.71 |
| Tingley Whittemore | Sell | Aug 17, 2026 | 2,279 | $0.71 |
| Ali Faraz | Sell | Aug 17, 2026 | 7,406 | $0.71 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$131.2M | -$115.9M | -$93.3M |
| Net Income | -$124.1M | -$111.1M | -$90.6M |
| Balance Sheet | |||
| Total Assets | $170.5M | $119.9M | $146.9M |
| Equity | - | $92.9M | $123.3M |
| ROE | - | -119.7% | -73.5% |
| Per Share | |||
| EPS | $-1.68 | $-1.31 | $-0.59 |
| Cash Flow | |||
| Operating CF | -$102.1M | -$90.5M | -$68.3M |
| CapEx | $1.2M | $1.0M | $618K |
Source: XBRL data in Tenaya Therapeutics Inc (TNYA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TNYA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $21.6M |
| Q1 2026 | 22 | $20.6M |
| Q4 2025 | 22 | $19.1M |
| Q3 2025 | 20 | $27.9M |
| Q2 2025 | 19 | $9.0M |
| Q1 2025 | 20 | $7.5M |
| Q4 2024 | 14 | $10.3M |
| Q3 2024 | 14 | $11.6M |
- Millennium Management+973.0K (+18%)
- Renaissance Technologies LLC+567.3K (+15%)
- Citadel Advisors LLC+366.8K (+9%)
- BlackRock+304.8K (+8%)
- Invesco Ltd+216.9K (+157%)
- Vanguard Capital Management LLC−1.38M (-16%)
- Two Sigma Investments−899.6K (-70%)
- Morgan Stanley−36.2K (-13%)
- Bank of America Corp−8.4K (-29%)
- Alphabet Inc−915.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 152 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TNYA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 5, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 6, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | - | |
| 10-K | Mar 11, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 8-K | Mar 5, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TNYA SEC filings: frequently asked questions
Are TNYA insiders buying or selling?
In the last 90 days, Tenaya Therapeutics Inc (TNYA) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $21,048 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TNYA stock?
As of June 30, 2026, the largest Tenaya Therapeutics Inc (TNYA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.2 million), Millennium Management ($4.8 million), Citadel Advisors LLC ($3.4 million), Renaissance Technologies LLC ($3.2 million), BlackRock ($3.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest TNYA SEC filings?
Tenaya Therapeutics Inc (TNYA) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 11, 2026.
What is TNYA's SEC CIK number?
Tenaya Therapeutics Inc (TNYA)'s SEC Central Index Key (CIK) is 1858848. EDGAR lists every TNYA filing under that number.
Ask anything about TNYA
The research agent reads TNYA's filings, financials, insider trades and 13F holders, then answers with sources.